AR051765A1 - Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas - Google Patents
Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulasInfo
- Publication number
- AR051765A1 AR051765A1 ARP050104743A ARP050104743A AR051765A1 AR 051765 A1 AR051765 A1 AR 051765A1 AR P050104743 A ARP050104743 A AR P050104743A AR P050104743 A ARP050104743 A AR P050104743A AR 051765 A1 AR051765 A1 AR 051765A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- molecule
- molecules conjugated
- cell absorption
- conjugated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una molécula conjugada que comprende, al menos una primera porcion (I) que incluye una secuencia de portador y, al menos, una segunda porcion (II) que incluye, al menos, una molécula de fármaco antitumoral o una molécula de inhibidor de proteasa, donde dicha molécula conjugada comprende en su porcion (I) aminoácidos D-enantioméricos. Además, la presente se refiere a composiciones farmacéuticos que contienen dicha molécula conjugada así como al uso de dicha molécula conjugada para tratamiento terapéutico. También se revelan métodos para aumentar la permeabilidad de célula.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04026934A EP1656951A1 (en) | 2004-11-12 | 2004-11-12 | Conjugates with enhanced cell uptake activity |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051765A1 true AR051765A1 (es) | 2007-02-07 |
Family
ID=34927367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104743A AR051765A1 (es) | 2004-11-12 | 2005-11-11 | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1656951A1 (es) |
JP (1) | JP2008519785A (es) |
CN (1) | CN101072589A (es) |
AR (1) | AR051765A1 (es) |
AU (1) | AU2005303949A1 (es) |
BR (1) | BRPI0517843A (es) |
CA (1) | CA2585421A1 (es) |
EA (1) | EA200700976A1 (es) |
IL (1) | IL182760A0 (es) |
WO (1) | WO2006050930A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
AU2007340158A1 (en) * | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence HIV-TAT polypeptides |
EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
US8895497B2 (en) | 2009-12-04 | 2014-11-25 | Dcb-Usa, Llc | Cathepsin S inhibitors |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CN104884078B (zh) * | 2012-10-17 | 2017-06-20 | 诺和诺德股份有限公司 | 用于口服肽递送的脂肪酸酰化d‑氨基酸 |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
CA3090060A1 (en) * | 2018-02-27 | 2019-09-06 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics and medicine |
CN108794581B (zh) * | 2018-06-26 | 2021-09-10 | 江苏大学 | 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040152084A1 (en) * | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
GB2341390B (en) * | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6593292B1 (en) * | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2002062396A2 (en) * | 2001-02-08 | 2002-08-15 | University Of Medicine And Dentistry Of New Jersey | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
DK2351844T3 (da) * | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
-
2004
- 2004-11-12 EP EP04026934A patent/EP1656951A1/en active Pending
-
2005
- 2005-11-09 AU AU2005303949A patent/AU2005303949A1/en not_active Abandoned
- 2005-11-09 WO PCT/EP2005/011991 patent/WO2006050930A2/en active Application Filing
- 2005-11-09 JP JP2007540568A patent/JP2008519785A/ja not_active Abandoned
- 2005-11-09 BR BRPI0517843-6A patent/BRPI0517843A/pt not_active IP Right Cessation
- 2005-11-09 CN CNA2005800387282A patent/CN101072589A/zh active Pending
- 2005-11-09 EP EP05811041A patent/EP1809334A2/en not_active Withdrawn
- 2005-11-09 CA CA002585421A patent/CA2585421A1/en not_active Abandoned
- 2005-11-09 EA EA200700976A patent/EA200700976A1/ru unknown
- 2005-11-11 AR ARP050104743A patent/AR051765A1/es not_active Application Discontinuation
-
2007
- 2007-04-23 IL IL182760A patent/IL182760A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005303949A1 (en) | 2006-05-18 |
JP2008519785A (ja) | 2008-06-12 |
CA2585421A1 (en) | 2006-05-18 |
IL182760A0 (en) | 2007-07-24 |
EP1656951A1 (en) | 2006-05-17 |
WO2006050930A3 (en) | 2007-04-26 |
BRPI0517843A (pt) | 2008-10-21 |
WO2006050930A2 (en) | 2006-05-18 |
EP1809334A2 (en) | 2007-07-25 |
CN101072589A (zh) | 2007-11-14 |
EA200700976A1 (ru) | 2007-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
BRPI0516577A (pt) | agentes terapêuticos com toxicidade diminuìda | |
CL2008001813A1 (es) | Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04). | |
CR9949A (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
ECSP088962A (es) | Nuevos herbicidas | |
WO2007061939A3 (en) | Metabolite derivatives of the hdac inhibitor fk228 | |
ATE430579T1 (de) | Transdermale botulinum-toxin-enthaltende verbindungen | |
BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
GT200400264A (es) | Agentes endoparasiticida para administracion topica | |
WO2007005941A3 (en) | Liver targeted conjugates | |
AR032293A1 (es) | Estuche farmaceutico | |
AR060827A1 (es) | Metodo para bloquear la infeccion por flavivirus, moleculas y usos | |
DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
CL2008003267A1 (es) | Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c. | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
UY29417A1 (es) | Agentes endoparasiticidas | |
CY1113525T1 (el) | Θεραπεια στοχευσης καθεψινης s | |
BRPI0621347B8 (pt) | composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |